vs
EXACT SCIENCES CORP（EXAS）与Monolithic Power Systems（MPWR）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Monolithic Power Systems的1.1倍（$878.4M vs $804.2M），Monolithic Power Systems净利率更高（24.0% vs -9.8%，领先33.8%），Monolithic Power Systems同比增速更快（26.1% vs 23.1%），过去两年Monolithic Power Systems的营收复合增速更高（25.9% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Monolithic Power Systems（简称MPS）是一家美国上市企业，总部位于华盛顿州柯克兰市，主营高性能电源管理类产品的研发、生产与销售，目前在全球范围内设有超过15个运营站点，业务覆盖多个国家和地区。
EXAS vs MPWR — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$804.2M
营收增速更快
MPWR
高出3.0%
23.1%
净利率更高
MPWR
高出33.8%
-9.8%
两年增速更快
MPWR
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $804.2M |
| 净利润 | $-86.0M | $193.2M |
| 毛利率 | 70.1% | 55.3% |
| 营业利润率 | -9.4% | 30.0% |
| 净利率 | -9.8% | 24.0% |
| 营收同比 | 23.1% | 26.1% |
| 净利润同比 | 90.1% | 43.1% |
| 每股收益（稀释后） | $-0.45 | $3.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMPWR
| Q1 26 | — | $804.2M | ||
| Q4 25 | $878.4M | $751.2M | ||
| Q3 25 | $850.7M | $737.2M | ||
| Q2 25 | $811.1M | $664.6M | ||
| Q1 25 | $706.8M | $637.6M | ||
| Q4 24 | $713.4M | $621.7M | ||
| Q3 24 | $708.7M | $620.1M | ||
| Q2 24 | $699.3M | $507.4M |
净利润EXASMPWR
| Q1 26 | — | $193.2M | ||
| Q4 25 | $-86.0M | $171.7M | ||
| Q3 25 | $-19.6M | $179.8M | ||
| Q2 25 | $-1.2M | $135.0M | ||
| Q1 25 | $-101.2M | $135.1M | ||
| Q4 24 | $-864.6M | $1.3B | ||
| Q3 24 | $-38.2M | $144.4M | ||
| Q2 24 | $-15.8M | $100.4M |
毛利率EXASMPWR
| Q1 26 | — | 55.3% | ||
| Q4 25 | 70.1% | 55.2% | ||
| Q3 25 | 68.6% | 55.1% | ||
| Q2 25 | 69.3% | 55.1% | ||
| Q1 25 | 70.8% | 55.4% | ||
| Q4 24 | 69.0% | 55.4% | ||
| Q3 24 | 69.4% | 55.4% | ||
| Q2 24 | 69.8% | 55.3% |
营业利润率EXASMPWR
| Q1 26 | — | 30.0% | ||
| Q4 25 | -9.4% | 26.6% | ||
| Q3 25 | -3.0% | 26.5% | ||
| Q2 25 | -0.3% | 24.8% | ||
| Q1 25 | -13.6% | 26.5% | ||
| Q4 24 | -122.8% | 26.3% | ||
| Q3 24 | -5.6% | 26.5% | ||
| Q2 24 | -3.8% | 23.0% |
净利率EXASMPWR
| Q1 26 | — | 24.0% | ||
| Q4 25 | -9.8% | 22.9% | ||
| Q3 25 | -2.3% | 24.4% | ||
| Q2 25 | -0.1% | 20.3% | ||
| Q1 25 | -14.3% | 21.2% | ||
| Q4 24 | -121.2% | 201.8% | ||
| Q3 24 | -5.4% | 23.3% | ||
| Q2 24 | -2.3% | 19.8% |
每股收益（稀释后）EXASMPWR
| Q1 26 | — | $3.92 | ||
| Q4 25 | $-0.45 | $3.50 | ||
| Q3 25 | $-0.10 | $3.74 | ||
| Q2 25 | $-0.01 | $2.81 | ||
| Q1 25 | $-0.54 | $2.81 | ||
| Q4 24 | $-4.69 | $25.71 | ||
| Q3 24 | $-0.21 | $2.95 | ||
| Q2 24 | $-0.09 | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.7B |
| 总资产 | $5.9B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASMPWR
| Q1 26 | — | $1.4B | ||
| Q4 25 | $964.7M | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $858.4M | $1.1B | ||
| Q1 25 | $786.2M | $1.0B | ||
| Q4 24 | $1.0B | $862.9M | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $946.8M | $1.3B |
股东权益EXASMPWR
| Q1 26 | — | $3.7B | ||
| Q4 25 | $2.4B | $3.5B | ||
| Q3 25 | $2.5B | $3.4B | ||
| Q2 25 | $2.5B | $3.2B | ||
| Q1 25 | $2.4B | $3.1B | ||
| Q4 24 | $2.4B | $3.0B | ||
| Q3 24 | $3.2B | $2.4B | ||
| Q2 24 | $3.2B | $2.2B |
总资产EXASMPWR
| Q1 26 | — | $4.4B | ||
| Q4 25 | $5.9B | $4.2B | ||
| Q3 25 | $5.9B | $4.1B | ||
| Q2 25 | $5.8B | $3.9B | ||
| Q1 25 | $5.7B | $3.7B | ||
| Q4 24 | $5.9B | $3.5B | ||
| Q3 24 | $6.7B | $2.9B | ||
| Q2 24 | $6.7B | $2.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASMPWR
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $104.9M | ||
| Q3 25 | $219.9M | $239.3M | ||
| Q2 25 | $89.0M | $237.6M | ||
| Q1 25 | $30.8M | $256.4M | ||
| Q4 24 | $47.1M | $167.7M | ||
| Q3 24 | $138.7M | $231.7M | ||
| Q2 24 | $107.1M | $141.0M |
自由现金流EXASMPWR
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $63.9M | ||
| Q3 25 | $190.0M | $196.8M | ||
| Q2 25 | $46.7M | $189.5M | ||
| Q1 25 | $-365.0K | $216.0M | ||
| Q4 24 | $10.7M | $102.9M | ||
| Q3 24 | $112.6M | $197.9M | ||
| Q2 24 | $71.2M | $109.5M |
自由现金流率EXASMPWR
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 8.5% | ||
| Q3 25 | 22.3% | 26.7% | ||
| Q2 25 | 5.8% | 28.5% | ||
| Q1 25 | -0.1% | 33.9% | ||
| Q4 24 | 1.5% | 16.5% | ||
| Q3 24 | 15.9% | 31.9% | ||
| Q2 24 | 10.2% | 21.6% |
资本支出强度EXASMPWR
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 5.5% | ||
| Q3 25 | 3.5% | 5.8% | ||
| Q2 25 | 5.2% | 7.2% | ||
| Q1 25 | 4.4% | 6.3% | ||
| Q4 24 | 5.1% | 10.4% | ||
| Q3 24 | 3.7% | 5.5% | ||
| Q2 24 | 5.1% | 6.2% |
现金转化率EXASMPWR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 1.90× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MPWR
暂无分部数据
